BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hazel K, O'Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis 2020;11:2040622319899297. [PMID: 32076497 DOI: 10.1177/2040622319899297] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Mu Y, Liu Y, Kishimura A, Mori T, Katayama Y. Effect of Size and Loading of Retinoic Acid in Polyvinyl Butyrate Nanoparticles on Amelioration of Colitis. Polymers (Basel) 2021;13:1472. [PMID: 34063206 DOI: 10.3390/polym13091472] [Reference Citation Analysis]
2 Seoane-Viaño I, Gómez-Lado N, Lázare-Iglesias H, García-Otero X, Antúnez-López JR, Ruibal Á, Varela-Correa JJ, Aguiar P, Basit AW, Otero-Espinar FJ, González-Barcia M, Goyanes A, Luzardo-Álvarez A, Fernández-Ferreiro A. 3D Printed Tacrolimus Rectal Formulations Ameliorate Colitis in an Experimental Animal Model of Inflammatory Bowel Disease. Biomedicines 2020;8:E563. [PMID: 33276641 DOI: 10.3390/biomedicines8120563] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
3 Tang B, Zhu J, Fang S, Wang Y, Vinothkumar R, Li M, Weng Q, Zheng L, Yang Y, Qiu R, Xu M, Zhao Z, Ji J. Pharmacological inhibition of MELK restricts ferroptosis and the inflammatory response in colitis and colitis-propelled carcinogenesis. Free Radic Biol Med 2021;172:312-29. [PMID: 34144192 DOI: 10.1016/j.freeradbiomed.2021.06.012] [Reference Citation Analysis]
4 Blagov A, Zhigmitova EB, Sazonova MA, Mikhaleva LM, Kalmykov V, Shakhpazyan NK, Orekhova VA, Orekhov AN. Novel Models of Crohn's Disease Pathogenesis Associated with the Occurrence of Mitochondrial Dysfunction in Intestinal Cells. Int J Mol Sci 2022;23:5141. [PMID: 35563530 DOI: 10.3390/ijms23095141] [Reference Citation Analysis]
5 Saber S, Youssef ME, Sharaf H, Amin NA, El-Shedody R, Aboutouk FH, El-Galeel YA, El-Hefnawy A, Shabaka D, Khalifa A, Saleh RA, Osama D, El-Zoghby G, Gobba NA. BBG enhances OLT1177-induced NLRP3 inflammasome inactivation by targeting P2X7R/NLRP3 and MyD88/NF-κB signaling in DSS-induced colitis in rats. Life Sci 2021;270:119123. [PMID: 33548287 DOI: 10.1016/j.lfs.2021.119123] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Xiang C, Liu M, Lu Q, Fan C, Lu H, Feng C, Yang X, Li H, Tang W. Blockade of TLRs-triggered macrophage activation by caffeic acid exerted protective effects on experimental ulcerative colitis. Cell Immunol 2021;365:104364. [PMID: 33932876 DOI: 10.1016/j.cellimm.2021.104364] [Reference Citation Analysis]
7 Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis. Drugs 2021;81:985-1002. [PMID: 33983615 DOI: 10.1007/s40265-021-01528-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Pabari RM, Tambuwala MM, Lajczak-McGinley N, Aljabali A, Kirby BP, Keely S, Ramtoola Z. Novel polyurethane based particulate formulations of infliximab reduce inflammation in DSS induced murine model of colitis - A preliminary study. Int J Pharm 2021;604:120717. [PMID: 34015378 DOI: 10.1016/j.ijpharm.2021.120717] [Reference Citation Analysis]
9 Glynn H, Knowles SR. A Phenomenological Investigation of Trauma in 18 Adults Living With Inflammatory Bowel Disease. Clin Nurs Res. [DOI: 10.1177/10547738221075649] [Reference Citation Analysis]
10 Sun Z, Li J, Wang W, Liu Y, Liu J, Jiang H, Lu Q, Ding P, Shi R, Zhao X, Yuan W, Tan X, Shi X, Xing Y, Mao T. Qingchang Wenzhong Decoction Accelerates Intestinal Mucosal Healing Through Modulation of Dysregulated Gut Microbiome, Intestinal Barrier and Immune Responses in Mice. Front Pharmacol 2021;12:738152. [PMID: 34557102 DOI: 10.3389/fphar.2021.738152] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Eronen H, Kolehmainen S, Koffert J, Koskinen I, Oksanen P, Jussila A, Huhtala H, Sipponen T, Ilus T. Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study. Scand J Gastroenterol 2022;:1-6. [PMID: 35238727 DOI: 10.1080/00365521.2022.2045350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Abdel-Wahab BA, Alkahtani SA, Alqahtani AA, Hassanein EHM. Umbelliferone ameliorates ulcerative colitis induced by acetic acid via modulation of TLR4/NF-κB-p65/iNOS and SIRT1/PPARγ signaling pathways in rats. Environ Sci Pollut Res Int 2022;29:37644-59. [PMID: 35066822 DOI: 10.1007/s11356-021-18252-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Li M, Yu L, Zhai Q, Liu B, Zhao J, Zhang H, Chen W, Tian F. Ganoderma applanatum polysaccharides and ethanol extracts promote the recovery of colitis through intestinal barrier protection and gut microbiota modulations. Food Funct 2021. [PMID: 34935013 DOI: 10.1039/d1fo03677g] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Reichardt SD, Amouret A, Muzzi C, Vettorazzi S, Tuckermann JP, Lühder F, Reichardt HM. The Role of Glucocorticoids in Inflammatory Diseases. Cells 2021;10:2921. [PMID: 34831143 DOI: 10.3390/cells10112921] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
15 Bastaki SMA, Amir N, Adeghate E, Ojha S. Nerolidol, a sesquiterpene, attenuates oxidative stress and inflammation in acetic acid-induced colitis in rats. Mol Cell Biochem 2021;476:3497-512. [PMID: 33999335 DOI: 10.1007/s11010-021-04094-5] [Reference Citation Analysis]
16 Xue P, Wang L, Xu J, Liu J, Pan X, Zhao Y, Xu H. Temperature-sensitive hydrogel for rectal perfusion improved the therapeutic effect of Kangfuxin liquid on DSS-induced ulcerative colitis mice: The inflammation alleviation and the colonic mucosal barriers repair. Int J Pharm 2020;589:119846. [PMID: 32891717 DOI: 10.1016/j.ijpharm.2020.119846] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
17 Bringer MA, Gabrielle PH, Bron AM, Creuzot-Garcher C, Acar N. The gut microbiota in retinal diseases. Exp Eye Res 2021;214:108867. [PMID: 34856206 DOI: 10.1016/j.exer.2021.108867] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Selvamani S, Mehta V, Ali El Enshasy H, Thevarajoo S, El Adawi H, Zeini I, Pham K, Varzakas T, Abomoelak B. Efficacy of Probiotics-Based Interventions as Therapy for Inflammatory Bowel Disease: A Recent Update. Saudi Journal of Biological Sciences 2022. [DOI: 10.1016/j.sjbs.2022.02.044] [Reference Citation Analysis]
19 Li B, Li Y, Li L, Yu Y, Gu X, Liu C, Long X, Yu Y, Zuo X. Hsa_circ_0001021 regulates intestinal epithelial barrier function via sponging miR-224-5p in ulcerative colitis. Epigenomics 2021;13:1385-401. [PMID: 34528447 DOI: 10.2217/epi-2021-0230] [Reference Citation Analysis]
20 Negi S, Saini S, Tandel N, Sahu K, Mishra RPN, Tyagi RK. Translating Treg Therapy for Inflammatory Bowel Disease in Humanized Mice. Cells 2021;10:1847. [PMID: 34440615 DOI: 10.3390/cells10081847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Mazur M, Włodarczyk J, Świerczyński M, Kordek R, Grzybowski MM, Olczak J, Fichna J. The Anti-Inflammatory Effect of Acidic Mammalian Chitinase Inhibitor OAT-177 in DSS-Induced Mouse Model of Colitis. Int J Mol Sci 2022;23:2159. [PMID: 35216274 DOI: 10.3390/ijms23042159] [Reference Citation Analysis]
22 Sinclair J, Dillon S, Bottoms L. Perceptions, beliefs and behaviors of nutritional and supplementary practices in inflammatory bowel disease. Sport Sci Health. [DOI: 10.1007/s11332-022-00901-8] [Reference Citation Analysis]
23 Mehrtash F. Sustained Crohn’s Disease Remission with an Exclusive Elemental and Exclusion Diet: A Case Report. GastrointestDisord 2021;3:129-38. [DOI: 10.3390/gidisord3030014] [Reference Citation Analysis]
24 Abdel Hamed EF, Mostafa NE, Hassan MM, Ibrahim MN, Elraey SM, Radwan M, Al-attar AR, Fawzy EM. Mitigation of Toxoplasma gondii-induced ileitis by Trichinellaspiralis infection pinpointing immunomodulation. J Parasit Dis. [DOI: 10.1007/s12639-022-01476-4] [Reference Citation Analysis]
25 Simsek M, de Boer NKH. Letter: off-label use of hyperbaric oxygen therapy in inflammatory bowel disease-Authors' reply. Aliment Pharmacol Ther 2020;52:216-7. [PMID: 32529768 DOI: 10.1111/apt.15806] [Reference Citation Analysis]
26 El Megeed KHA, Saleh SAB, Mohamed AE, Alphonse Anwar C. Predictors of surgical intervention in patients with inflammatory bowel disease (two-center study). Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00050-3] [Reference Citation Analysis]
27 Nadpara N, Reichenbach ZW, Ehrlich AC, Friedenberg F. Current Status of Medical Therapy for Inflammatory Bowel Disease: The Wealth of Medications. Dig Dis Sci 2020;65:2769-79. [PMID: 32661765 DOI: 10.1007/s10620-020-06471-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
28 Stojek M, Jabłońska A, Adrych K. The Role of Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease. J Clin Med 2021;10:4055. [PMID: 34575166 DOI: 10.3390/jcm10184055] [Reference Citation Analysis]
29 Chen P, Zhou G, Lin J, Li L, Zeng Z, Chen M, Zhang S. Serum Biomarkers for Inflammatory Bowel Disease. Front Med (Lausanne). 2020;7:123. [PMID: 32391365 DOI: 10.3389/fmed.2020.00123] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
30 Zandeh-Rahimi Y, Panahi N, Hesaraki S, Shirazi-Beheshtiha SH. Protective Effects of Phoenixin-14 Peptide in the Indomethacin-Induced Duodenal Ulcer: An Experimental Study. Int J Pept Res Ther 2022;28:43. [PMID: 35002587 DOI: 10.1007/s10989-021-10314-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Moreno LO, Fernández-tomé S, Abalo R. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. Biologics 2021;1:189-210. [DOI: 10.3390/biologics1020012] [Reference Citation Analysis]
32 Kim JS, Kim YR, Jang S, Wang SG, Cho E, Mun SJ, Jeon HI, Kim HK, Min SJ, Yang CS. Mito-TIPTP Increases Mitochondrial Function by Repressing the Rubicon-p22phox Interaction in Colitis-Induced Mice. Antioxidants (Basel) 2021;10:1954. [PMID: 34943057 DOI: 10.3390/antiox10121954] [Reference Citation Analysis]
33 Sadowska B, Rywaniak J, Cichocka A, Cichocka K, Żuchowski J, Wójcik-Bojek U, Więckowska-Szakiel M, Różalska B. Phenolic and Non-Polar Fractions of the Extracts from Fruits, Leaves, and Twigs of Elaeagnus rhamnoides (L.) A. Nelson-The Implications for Human Barrier Cells. Molecules 2020;25:E2238. [PMID: 32397559 DOI: 10.3390/molecules25092238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Antunes JC, Seabra CL, Domingues JM, Teixeira MO, Nunes C, Costa-Lima SA, Homem NC, Reis S, Amorim MTP, Felgueiras HP. Drug Targeting of Inflammatory Bowel Diseases by Biomolecules. Nanomaterials (Basel) 2021;11:2035. [PMID: 34443866 DOI: 10.3390/nano11082035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Yang L, Luo H, Tan D, Zhang S, Zhong Z, Wang S, Vong CT, Wang Y. A recent update on the use of Chinese medicine in the treatment of inflammatory bowel disease. Phytomedicine 2021;92:153709. [PMID: 34560518 DOI: 10.1016/j.phymed.2021.153709] [Reference Citation Analysis]
36 de Graaf DM, Wang RX, Amo-aparicio J, Lee JS, Dowdell AS, Tengesdal IW, Marchetti C, Colgan SP, Joosten LAB, Dinarello CA. IL-38 Gene Deletion Worsens Murine Colitis. Front Immunol 2022;13:840719. [DOI: 10.3389/fimmu.2022.840719] [Reference Citation Analysis]
37 Ma S, Zhang J, Liu H, Li S, Wang Q. The Role of Tissue-Resident Macrophages in the Development and Treatment of Inflammatory Bowel Disease. Front Cell Dev Biol 2022;10:896591. [PMID: 35721513 DOI: 10.3389/fcell.2022.896591] [Reference Citation Analysis]
38 Eder P, Zielińska A, Karczewski J, Dobrowolska A, Słomski R, Souto EB. How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions. J Nanobiotechnology 2021;19:346. [PMID: 34715852 DOI: 10.1186/s12951-021-01090-1] [Reference Citation Analysis]
39 Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases. Front Cell Dev Biol 2021;9:612830. [PMID: 33614645 DOI: 10.3389/fcell.2021.612830] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Bunt DV, Minnaard AJ, El Aidy S. Potential Modulatory Microbiome Therapies for Prevention or Treatment of Inflammatory Bowel Diseases. Pharmaceuticals (Basel) 2021;14:506. [PMID: 34073220 DOI: 10.3390/ph14060506] [Reference Citation Analysis]
41 Zhao H, Qian YZ, Qian HH. Interleukin-12B gene rs6887695 and rs2288831 polymorphisms are associated with an increased risk of ulcerative colitis development in Chinese Han population: A case-control study. J Clin Lab Anal 2020;34:e23472. [PMID: 32666631 DOI: 10.1002/jcla.23472] [Reference Citation Analysis]
42 Casalegno Garduño R, Däbritz J. New Insights on CD8+ T Cells in Inflammatory Bowel Disease and Therapeutic Approaches. Front Immunol 2021;12:738762. [PMID: 34707610 DOI: 10.3389/fimmu.2021.738762] [Reference Citation Analysis]
43 Bonnaud G, Haennig A, Altwegg R, Caron B, Boivineau L, Zallot C, Gilleta de Saint-Joseph C, Moreau J, Gonzalez F, Reynaud D, Faure P, Aygalenq P, Combis JM, Peyrin-Biroulet L. Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI® on quality of life and quality of care in patients with inflammatory bowel disease. Scand J Gastroenterol 2021;56:530-6. [PMID: 33691075 DOI: 10.1080/00365521.2021.1894602] [Reference Citation Analysis]
44 Barreto de Albuquerque J, Mueller C, Gungor B. Tissue-Resident T Cells in Chronic Relapsing-Remitting Intestinal Disorders. Cells 2021;10:1882. [PMID: 34440651 DOI: 10.3390/cells10081882] [Reference Citation Analysis]
45 Abraham B, Eksteen B, Nedd K, Kale H, Patel D, Stephens J, Shelbaya A, Chambers R, Soonasra A. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study). Adv Ther 2022;39:2109-27. [PMID: 35296993 DOI: 10.1007/s12325-022-02104-6] [Reference Citation Analysis]